Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2016-09-22 Regulatory Filings
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Response to ASX Price Query 5 pages 704.8KB
Regulatory Filings Classification · 100% confidence The document is a letter from ASX Compliance to Phosphagenics Limited regarding a price query due to unusual trading activity in the company's securities. The letter requests confirmation about any undisclosed information that might explain the trading, compliance with listing rules, and potential need for a trading halt. The company's response confirms no undisclosed information exists and compliance with listing rules. The document is a regulatory communication related to market compliance and disclosure obligations, not a financial report, earnings release, or other specific report type. It is a regulatory filing responding to a compliance inquiry under ASX Listing Rules, specifically Listing Rule 3.1 and 3.1A. The document length is under 10,000 characters and consists mainly of correspondence and compliance statements. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document.
2016-09-22 English
Phosphagenics Updates Long Term Incentive Scheme 1
Regulatory Filings Classification · 95% confidence The document is an announcement from Phosphagenics Limited regarding updates to its long term incentive scheme for employees and directors. It discusses the replacement of the current scheme with a new Conditional Options Scheme, details about option vesting, exercise price, and conditions for participation. It also mentions that shareholder approval will be sought at the next AGM. The document does not contain financial statements, detailed financial performance data, or full report content. It is a corporate announcement about management compensation plans and upcoming shareholder meeting agenda items, not a full report or detailed presentation. Therefore, it fits best under Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2016-09-11 English
Phosphagenics Begins Feed Efficiency Study in Poultry 2 pages 250.3KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Phosphagenics Limited about the initiation of a poultry feed efficiency study as part of their Animal Health and Nutrition program. It is a company announcement describing a new study and its expected timeline, not a financial report, earnings release, or regulatory filing. The document does not contain financial statements, audit information, management changes, or voting results. It is a general corporate update on a research program, which fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2016-08-30 English
June 2016 Half-year Financial Report and Appendix 4D 23 pages 445.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Phosphagenics Limited Appendix 4D Half Year Report' and covers the half year ended 30 June 2016. It includes detailed financial statements such as the Consolidated Income Statement, Balance Sheet, Statement of Cash Flows, Directors' Report, and Auditor's Review Report. The content includes comprehensive financial data, operational review, and management commentary for the half-year period. The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or summary. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data and analysis. H1 2016
2016-08-25 English
Phosphagenics Half Year Financial Results 2 pages 79.7KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Phosphagenics Half Year Financial Results' and dated 26 August 2016, reporting financial results for the half-year ended 30 June 2016. It contains a financial summary with revenue, net loss, cash position, and operational highlights. The content includes actual financial data and analysis for a period shorter than a full fiscal year, consistent with an interim or quarterly report. The document length is 4726 characters, which is sufficient to contain substantive financial data rather than just an announcement or summary. There is no indication that this is a full annual report or just an earnings release with key highlights only. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2016
2016-08-25 English
Phosphagenics July Newsletter 6 pages 1.3MB
AGM Information Classification · 90% confidence The document is a detailed shareholder newsletter from Phosphagenics dated July 2016. It provides updates on business progress, partnerships, clinical studies, and strategic direction. It references the Annual General Meeting (AGM) held in May and mentions that the last shareholder update was provided in conjunction with the AGM. The content is focused on business updates, partnership agreements, clinical progress, and strategic plans rather than formal financial statements or regulatory filings. The document is not a full annual or quarterly report, nor is it an earnings release or audit report. It is also not a call transcript or a proxy solicitation. The newsletter is intended as a shareholder communication providing information similar to what might be shared at or around an AGM but is not the AGM materials themselves. Given the nature of the document as a shareholder update/newsletter with business and strategic updates, the most appropriate classification is AGM Information (AGM-R), as it aligns with presentations and materials shared during or in relation to the Annual General Meeting and shareholder communications around that event.
2016-07-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.